ConductScience.org, home

Paper27436699

Changes in the inflammatory markers with advancing stages of diabetic nephropathy and the role of pentraxin-3.

Uzun S and 9 others. Ren Fail, 2016. Cited by 20 papers, by iCite.

Cite this record

ConductScience Library. Changes in the inflammatory markers with advancing stages of diabetic nephropathy and the role of pentraxin-3. Papers, record 27436699. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/27436699

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Changes in the inflammatory markers with advancing stages of diabetic nephropathy and the role of pentraxin-3.
PubMed
Journal
Ren Fail
PubMed
Year
2016
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
20
iCite
Relative citation ratio, by iCite
0.89
iCite
Revised in PubMed
2026-01-27
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Uzun SSami
2Ozari MMuge
3Gursu MMeltem
4Karadag SSerhat
5Behlul AAhmet
6Sari SSoner
7Koldas MMacit
8Demir SSecil
9Karaali ZZeynep
10Ozturk SSavas

Source PubMed

Download CSV of authors

Topics19

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
C-Reactive ProteinMajor topic
Diabetes Mellitus, Type 2Major topic
Diabetic NephropathiesMajor topic
Interleukin-1Major topic
Serum Amyloid P-ComponentMajor topic
Tumor Necrosis Factor-alphaMajor topic
Aged
Albuminuria
Biomarkers
Cross-Sectional Studies
Female
Glomerular Filtration Rate
Humans
Inflammation
Linear Models
Male
Middle Aged
Turkey
Pentraxins

Source PubMed

Download CSV of topics

Cited by14

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.

PMIDTitleJournalYearIn PapersSource
40620843Impact of Albuminuria and Renal Dysfunction on the Anemia-Improving Effect of SGLT2 Inhibitors in Patients With Type 2 Diabetes: A Real-World Observational Study.J Diabetes Res2025https://conductscience.org/library/papers/40620843PubMed
40520240Association between skeletal muscle mass to visceral fat area ratio and insulin resistance in type 2 diabetes.J Diabetes Metab Disord2025https://conductscience.org/library/papers/40520240PubMed
40332236Association Between Pentraxins and Obesity in Prediabetes and Newly Diagnosed Type 2 Diabetes Mellitus Patients.Int J Mol Sci2025https://conductscience.org/library/papers/40332236PubMed
40299501Pentraxin-3 as a Biomarker in Diabetes Mellitus: Insights into Inflammation, Vascular Complications, and Modulation by Antidiabetic Medications.Biomedicines2025https://conductscience.org/library/papers/40299501PubMed
36051390A meta-analysis of genome-wide gene expression differences identifies promising targets for type 2 diabetes mellitus.Front Endocrinol (Lausanne)2022https://conductscience.org/library/papers/36051390PubMed
35708187Review of potential biomarkers of inflammation and kidney injury in diabetic kidney disease.Diabetes Metab Res Rev2022https://conductscience.org/library/papers/35708187PubMed
32662255Serum Levels of Adipocyte Fatty Acid-Binding Protein Are Associated with Rapid Renal Function Decline in Patients with Type 2 Diabetes Mellitus and Preserved Renal Function.Diabetes Metab J2020https://conductscience.org/library/papers/32662255PubMed
32661627Pentraxin-3 and adropin as inflammatory markers of early renal damage in type 2 diabetes patients.Int Urol Nephrol2020https://conductscience.org/library/papers/32661627PubMed
32384513Monocyte-lymphocyte ratio is a valuable predictor for diabetic nephropathy in patients with type 2 diabetes.Medicine (Baltimore)2020https://conductscience.org/library/papers/32384513PubMed
32133797Roles of pattern recognition receptors in diabetic nephropathy.J Zhejiang Univ Sci B2020https://conductscience.org/library/papers/32133797PubMed
29675428PTX3: A Potential Biomarker in Thyroid Associated Ophthalmopathy.Biomed Res Int2018https://conductscience.org/library/papers/29675428PubMed
29275488The renoprotective effect and safety of a DPP-4 inhibitor, sitagliptin, at a small dose in type 2 diabetic patients with a renal dysfunction when changed from other DPP-4 inhibitors: REAL trial.Clin Exp Nephrol2018https://conductscience.org/library/papers/29275488PubMed
28861072UroPathogenic Escherichia coli (UPEC) Infections: Virulence Factors, Bladder Responses, Antibiotic, and Non-antibiotic Antimicrobial Strategies.Front Microbiol2017https://conductscience.org/library/papers/28861072PubMed
28119515Association of Pentraxin 3 Gene Polymorphisms with Susceptibility to Diabetic Nephropathy.Med Sci Monit2017https://conductscience.org/library/papers/28119515PubMed

Download CSV of cited by

Genes6

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/27436699

GET https://conductscience.org/api/papers/v1/27436699/authors